NovoCure Statistics
Share Statistics
NovoCure has 111.49M
shares outstanding. The number of shares has increased by 2.14%
in one year.
| Shares Outstanding | 111.49M |
| Shares Change (YoY) | 2.14% |
| Shares Change (QoQ) | 1.58% |
| Owned by Institutions (%) | 84.59% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 8 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 5.44M, so 4.88% of the outstanding
shares have been sold short.
| Short Interest | 5.44M |
| Short % of Shares Out | 4.88% |
| Short % of Float | 7.73% |
| Short Ratio (days to cover) | 5.61 |
Valuation Ratios
The PE ratio is -19.06 and the forward
PE ratio is -8.71.
NovoCure's PEG ratio is
0.95.
| PE Ratio | -19.06 |
| Forward PE | -8.71 |
| PS Ratio | 5.31 |
| Forward PS | 1.3 |
| PB Ratio | 8.92 |
| P/FCF Ratio | -46.42 |
| PEG Ratio | 0.95 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for NovoCure.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.46,
with a Debt / Equity ratio of 1.9.
| Current Ratio | 1.46 |
| Quick Ratio | 1.42 |
| Debt / Equity | 1.9 |
| Debt / EBITDA | -6.31 |
| Debt / FCF | -9.87 |
| Interest Coverage | -16.48 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $406,733.87 |
| Profits Per Employee | $-113,324.6 |
| Employee Count | 1,488 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 3.91 |
Taxes
| Income Tax | 37.47M |
| Effective Tax Rate | -28.56% |
Stock Price Statistics
The stock price has increased by -18.67% in the
last 52 weeks. The beta is 0.73, so NovoCure's
price volatility has been higher than the market average.
| Beta | 0.73 |
| 52-Week Price Change | -18.67% |
| 50-Day Moving Average | 18.04 |
| 200-Day Moving Average | 20.35 |
| Relative Strength Index (RSI) | 46.1 |
| Average Volume (20 Days) | 926,376 |
Income Statement
In the last 12 months, NovoCure had revenue of 605.22M
and earned -168.63M
in profits. Earnings per share was -1.56.
| Revenue | 605.22M |
| Gross Profit | 468.04M |
| Operating Income | -170.5M |
| Net Income | -168.63M |
| EBITDA | -108.26M |
| EBIT | -120.82M |
| Earnings Per Share (EPS) | -1.56 |
Full Income StatementBalance Sheet
The company has 163.77M in cash and 683.35M in
debt, giving a net cash position of -519.59M.
| Cash & Cash Equivalents | 163.77M |
| Total Debt | 683.35M |
| Net Cash | -519.59M |
| Retained Earnings | -1.15B |
| Total Assets | 1.25B |
| Working Capital | 346M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -26.37M
and capital expenditures -42.85M, giving a free cash flow of -69.22M.
| Operating Cash Flow | -26.37M |
| Capital Expenditures | -42.85M |
| Free Cash Flow | -69.22M |
| FCF Per Share | -0.64 |
Full Cash Flow StatementMargins
Gross margin is 77.33%, with operating and profit margins of -28.17% and -27.86%.
| Gross Margin | 77.33% |
| Operating Margin | -28.17% |
| Pretax Margin | -21.67% |
| Profit Margin | -27.86% |
| EBITDA Margin | -17.89% |
| EBIT Margin | -28.17% |
| FCF Margin | -11.44% |
